This randomized, double-blind, placebo-controlled will evaluate the efficacy and safety of CIN-107 in patients with uHTN and CKD. Approximately 300 patients will be randomized in a 1:1:1 ratio into 1 of the 3 treatment groups (placebo, low dose treatment strategy and high dose treatment strategy).~The study will consist of the following 3 periods:~A Screening Period of up to 5 weeks;~A Double-Blind Treatment Period of 26 weeks; and~A Follow-Up Period of 2 weeks.~Patients will complete the study in approximately 8 months.
This study will evaluate the efficacy and safety of CIN-107 for the treatment of hypertension in patients with uncontrolled hypertension (uHTN) and Chronic Kidney Disease (CKD).